Media stories about Hutchison China MediTech (NASDAQ:HCM) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hutchison China MediTech earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.4109200359184 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Hutchison China MediTech (HCM) traded down $0.21 during trading on Friday, reaching $39.56. 64,878 shares of the company’s stock traded hands, compared to its average volume of 85,854. The company has a current ratio of 1.84, a quick ratio of 1.73 and a debt-to-equity ratio of 0.09. Hutchison China MediTech has a 52-week low of $12.62 and a 52-week high of $42.25.

Several research analysts have weighed in on the stock. BidaskClub raised shares of Hutchison China MediTech from a “hold” rating to a “buy” rating in a report on Saturday, December 30th. Canaccord Genuity increased their price target on shares of Hutchison China MediTech to $38.00 and gave the company a “buy” rating in a report on Monday, October 16th.

WARNING: “Hutchison China MediTech (HCM) Earns Coverage Optimism Rating of 0.23” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at

Hutchison China MediTech Company Profile

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Insider Buying and Selling by Quarter for Hutchison China MediTech (NASDAQ:HCM)

Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with's FREE daily email newsletter.